Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland . Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco ), the European Union, Japan , Canada , Australia and Switzerland .
At the end of September 2006, Tracleer® was commercially available in 35 countries worldwide. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. Actelion’s employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs.
See below for employment opportunities with us!
